Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant
cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological …

Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Abstract N 6-methyladenosine (m6A) modification of gene transcripts plays critical roles in
cancer. Here we report transcriptomic m6A profiling in 98 tissue samples from 65 individuals …

Multiple myeloma (MM) is still incurable partially due to lacking effective therapeutic targets.
Aberrant N6-methyladenosine (m6A) RNA modification plays a vital role in many cancers …

Simple Summary Ovarian cancer is the gynaecologic malignant tumour with the highest
mortality. Most patients are already in the advanced stage when they are found, and the 5 …

Aberrant epigenetic drivers or suppressors contribute to LUAD progression and drug
resistance, including KRAS, PTEN, Keap1. Human Plant Homeodomain (PHD) finger …

Multiple myeloma (MM) is a heterogeneous and incurable tumor characterized by the
malignant proliferation of plasma cells. It is necessary to clarify the heterogeneity of MM and …

Abstract N6-methyladenosine (m 6 A) modification is the most abundant post-transcriptional
regulation of RNAs in eukaryotes. Dysregulation of m 6 A readers, writers, and erasers can …

Simple Summary Recently, despite the common application of various novel therapies (eg,
immunotherapy and stem cell transplantation) in hematologic tumors, hematologic …

One of the most common hematological malignancies is multiple myeloma (MM) that its
mortality and morbidity have increased. The incidence rate of MM is suggested to be higher …